Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRT-064040
- Development stage
- Phase 2
- Lead developer
- Sichuan Prite Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
PRT-064040 is a **chemical drug** under development as a potential treatment for **migraine disorders**, specifically for the acute treatment of migraine. It is currently formulated as a **nasal spray** and is in **Phase 1 clinical trials**. The primary focus in early trials is on evaluating its **safety, tolerability, and pharmacokinetic characteristics** in healthy adult subjects after single and multiple doses. The drug was initially developed by Sichuan Purity Pharmaceutical Co., Ltd., which continues to lead its clinical development[1][4][6][8][9]. The specific mechanism of action and pharmacological target have not been publicly disclosed as of the latest updates.
Beyond the preview
Go deeper on PRT-064040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRT-064040.